Project ID: AE_20200512_COL_MKAVOUSI_MBOS_CHARGE_1000G_CAC.
Collaboration for mapping targets from the CHARGE Consortium 1000G GWAS on coronary artery calcification (CAC) with Maryam Kavousi, Patricia Peyser, and Maxime Bos.
We have bulk RNAseq (n = 635 samples) and single-cell RNAseq data, genome-wide methylation (Illumina 450K) in n ± 600, as well as overlapping genetic data for ±2,100 individuals with extensive histological plaque characterisation. We will address the following questions:
Ideally, we would like to map the variants to the expression and methylation data (molecular QTL mapping), but this is pending finalizing our molQTL mapping.
We expect new plasma-based OLINK data (for the ‘TO_AITION’ projecty) in Q4 2020. We agreed that we would keep this in mind, we could run some additional analyses when asked during the revision stage of the manuscript.
We will use the last dataset from the scRNAseq data, including 35 individuals, to project target genes.
For the genetic analyses we will perform regression analyses adjusted for age, sex (where applicable) and principal components. So, we will apply the following model:
model 1: phenotype ~ age + sex + chip-used + PC1 + PC2 + year-of-surgery
phenotypes are:
calcification, coded Calc.bin no/minor vs. moderate/heavy stainingcollagen, coded Collagen.bin no/minor vs. moderate/heavy stainingfat10, coded Fat.bin_10 no/<10% fat vs. >10% fatfat40, coded Fat.bin_40 no/<40% fat vs. >40% fatintraplaque hemorrhage, coded IPH.bin no vs. yesmacrophages (CD68), coded macmean0 mean of computer-assisted calculation CD68+ region of interestsmooth muscle cells (alpha-actin), coded smcmean0 mean of computer-assisted calculation SMA+ region of interestintraplaque vessel density (CD34), coded vessel_density manually counted CD34+ cells per 3-4 hotspotsmast cells, coded Mast_cells_plaque manually counted mast cell tryptase+ cells (https://academic.oup.com/eurheartj/article/34/48/3699/484981)neutrophils (CD66b), coded neutrophils manually counted CD66b+ cells (https://pubmed.ncbi.nlm.nih.gov/20595650/)Continuous variables were inverse-rank normal transformated, indicated by _rankNorm.
For the expression analysis we used carotid plaque-derived bulk RNAseq data and queried it for the gene list. Below a graph showing the overall expression of the genes (not all are in the data) compared to the mean expression of 1,000 randomly picked genes.
Figure 1: Overall expression of target genes in carotid plaques from the Athero-Express Biobank Study
We assessed the correlation with plaque characteristics (mentioned above) and secondary major adverse cardiovascular events (MACE [major]) at 30 days and 3 years after CEA.
We projected target genes to the single-cell RNAseq data derived from 37 carotid plaque samples. We identified cell communities (Figure 2), mapped and projected target gene expression to the cell communities (Figure 3).
Figure 2: Cell communities identified in carotid plaques from the Athero-Express Biobank Study
Figure 3: Dotplot showing expression of target genes per cell type in carotid plaques from the Athero-Express Biobank Study
Quantitative trait loci mapping has not finished. This could be added at a later stage.
Permission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation files (the “Software”), to deal in the Software without restriction, including without limitation the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to whom the Software is furnished to do so, subject to the following conditions:
The above copyright notice and this permission notice shall be included in all copies or substantial portions of the Software.
THE SOFTWARE IS PROVIDED “AS IS”, WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.
Reference: http://opensource.org.